Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the US.

The open-label Phase 2/3 uveal melanoma trial tested the …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844